Clinical trials
Alzheimer’s disease clinical trials
A progressive brain disorder that affects memory and thinking. We’re tracking 601 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07094516RecruitingPhase 2
Testing VHB937 for early Alzheimer's disease
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
Phoenix, ArizonaAges 50–85 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07007208RecruitingPhase 2
Brain imaging study to detect early Alzheimer's risk
This study uses brain scans (MRI and PET) to look at a tiny brain region called the locus coeruleus, which may show early signs of Alzheimer's disease. Researchers want to see if changes in this area are linked to thinking skills and future memory decline.
ToulouseAges 60–100 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06948929Recruiting
Gut health supplement trial for Alzheimer's patients in Hong Kong
This trial tests whether a daily supplement of friendly bacteria and prebiotics (called a synbiotic) can help people with Alzheimer's. It looks at how the supplement affects thinking, behavior, and daily life over time.
ShatinAges 60–90 - NCT06924359Recruiting
Eye scans and blood tests for early Alzheimer's detection
This study uses special eye scans and blood tests to find early signs of Alzheimer's disease. It aims to detect the disease before memory loss becomes severe, so treatment can start sooner.
BeijingAges 50 years+ - NCT06871839Recruiting
A study of lencanumab for early Alzheimer's disease
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
BeijingAges 50–90 - NCT05059158Recruiting
Study how the brain clears amyloid in Alzheimer’s
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
München, BavariaAges 50–85 - NCT06810960Recruiting
Leqembi use in South Korean Alzheimer's patients
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
Nutley, New JerseyAges 19 years+ - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Homewood, AlabamaAges 55–90 - NCT06657768RecruitingPhase 1
Study of LY4006895 for healthy people and those with early Alzheimer's
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
Los Alamitos, CaliforniaAges 45–85 - NCT06668610Recruiting
Brain stimulation study for mild memory problems
This study tests a non-invasive brain stimulation technique (tDCS) combined with brain wave recording (EEG) to see if it can improve memory and thinking in people with mild cognitive impairment or early dementia.
Caserta, ItalyAges 55–85 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
Atlantis, FloridaAges 60–90 - NCT06274528RecruitingPhase 2
DORA and lemborexant in Alzheimer's biomarkers study
This study is testing whether a sleep medication called lemborexant can improve sleep and reduce Alzheimer's-related proteins in healthy older adults with no memory problems. It could help find new ways to delay or prevent Alzheimer's disease.
St Louis, MissouriAges 65 years+ - NCT06189963RecruitingPhase 1/Phase 2
Cell therapy trial for moderate Alzheimer's disease
This trial tests a new immune cell therapy (SNK01) for people with moderate Alzheimer's disease. The goal is to see if it can slow down memory and thinking decline.
Glendale, CaliforniaAges 40–85 - NCT05573490Recruiting
Lifestyle program study for early-onset Alzheimer’s
This study tests a structured lifestyle intervention to help people with early-onset Alzheimer’s disease. It is designed for adults with confirmed Alzheimer’s-related brain changes, and may help with symptoms or day-to-day functioning.
Indianapolis, IndianaAges 40–75 - NCT05457998Enrolling by invitation
Study of Alzheimer’s brain markers using memory testing
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
Providence, Rhode IslandAges 50–80 - NCT05205980Recruiting
Training practice to help prevent falls in Alzheimer’s
This trial tests whether a specific “training practice” can reduce falls in people with probable Alzheimer’s disease. It may help by improving safe walking and balance after doing the training.
Valdosta, GeorgiaAges 65–90 - NCT05020106Recruiting
Tests Alzheimer’s core blood/brain markers to set diagnostic cutoffs
This study checks Alzheimer’s “core biomarkers” to find the best cut-off values for diagnosing Alzheimer’s disease and related conditions. It may help doctors more accurately tell Alzheimer’s, mild cognitive changes, and other causes of memory problems apart.
Beijing, Beijing MunicipalityAges 55–75 - NCT04629547RecruitingPhase 2
Sleep study to help prevent Alzheimer’s disease
This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.
St Louis, MissouriAges 65 years+ - NCT04042532Enrolling by invitation
Theta-burst brain stimulation for younger-onset Alzheimer’s
This trial tests whether a form of brain stimulation (theta-burst stimulation) can improve thinking and memory in people with younger-onset Alzheimer’s. It also compares results with people without dementia who meet similar age and health requirements.
Taoyuan, GuishanAges 50–75 - NCT03653156Recruiting
Aging and brain study for mild memory loss and dementia
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
Hefei, AnhuiAges 18 years+ - NCT06058234Recruiting
Tracking Alzheimer’s treatment for Medicare patients in early stages
This study tracks how well a certain type of Alzheimer’s treatment works for people on Medicare who are in the early stages of the disease. The goal is to collect real-world information about the drug’s benefits and risks.
Baltimore, MarylandAges Any age - NCT07027072RecruitingPhase 2
Testing KDS2010 for early Alzheimer's memory loss
This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.
Gwangju, GwangjuAges 50–85
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer’s disease?
- Yes. Clin2 currently lists 601 recruiting alzheimer’s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer’s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.